Treat-to-target

Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors
Xavier M Teitsma, Johannes W G Jacobs, Paco M J Welsing, Pascal H P de Jong, Johanna M W Hazes, Angelique E A M Weel, Attila Pethö-Schramm, Michelle E A Borm, Jacob M van Laar, Floris P J G Lafeber, Johannes W J Bijlsma

Annals of the Rheumatic Diseases Sep 2018, 77 (9) 1261-1267; DOI: 10.1136/annrheumdis-2018-213035
Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)
Sofia Ramiro, Robert BM Landewé, Désirée van der Heijde, Alexandre Sepriano, Oliver FitzGerald, Mikkel Ostergaard, Joanne Homik, Ori Elkayam, J Carter Thorne, Margaret Larche, Gianfranco Ferraciolli, Marina Backhaus, Gilles Boire, Bernard Combe, Thierry Schaeverbeke, Alain Saraux, Maxime Dougados, Maurizio Rossini, Marcello Govoni, Luigi Sinigaglia, Alain G Cantagrel, Cornelia F Allaart, Cheryl Barnabe, Clifton O Bingham, Paul P Tak, Dirkjan van Schaardenburg, Hilde Berner Hammer, Rana Dadashova, Edna Hutchings, Joel Paschke, Walter P Maksymowych

Annals of the Rheumatic Diseases Apr 2020, 79 (4) 453-459; DOI: 10.1136/annrheumdis-2019-216819
Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials
Maxime MA Verhoeven, Marjolein JH de Hair, Janneke Tekstra, Johannes WJ Bijlsma, Jacob M van Laar, Attila Pethoe-Schramm, Michelle EA Borm, Evert-Jan ter Borg, Suzanne P Linn-Rasker, Xavier M Teitsma, Floris PJG Lafeber, Johannes WG Jacobs, Paco MJ Welsing

Annals of the Rheumatic Diseases Oct 2019, 78 (10) 1333-1338; DOI: 10.1136/annrheumdis-2019-215304
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
Eric F Morand, Teodora Trasieva, Anna Berglind, Gabor G Illei, Raj Tummala

Annals of the Rheumatic Diseases May 2018, 77 (5) 706-713; DOI: 10.1136/annrheumdis-2017-212504
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
Josef S Smolen, Jürgen Braun, Maxime Dougados, Paul Emery, Oliver FitzGerald, Philip Helliwell, Arthur Kavanaugh, Tore K Kvien, Robert Landewé, Thomas Luger, Philip Mease, Ignazio Olivieri, John Reveille, Christopher Ritchlin, Martin Rudwaleit, Monika Schoels, Joachim Sieper, Martinus de Wit, Xenofon Baraliakos, Neil Betteridge, Ruben Burgos-Vargas, Eduardo Collantes-Estevez, Atul Deodhar, Dirk Elewaut, Laure Gossec, Merryn Jongkees, Mara Maccarone, Kurt Redlich, Filip van den Bosch, James Cheng-Chung Wei, Kevin Winthrop, Désirée van der Heijde

Annals of the Rheumatic Diseases Jan 2014, 73 (1) 6-16; DOI: 10.1136/annrheumdis-2013-203419

Log in using your username and password

Main menu

Log in using your username and password

You are here

Treat-to-target